6 курс / Кардиология / Джон_Кэмм_Болезни_сердца_и_сосудов_2011
.pdf187.Goldmann B.U. et al. Quantitative bedside testing of troponin T: is it equal to laboratory testing? The Cardiac Reader Troponin T (CARE T) study // Clin. Lab. - 2004. - Vol. 50. - P. 1-10.
188.Sylven C. et al. Excellent reliability of nurse-based bedside diagnosis of acute myocardial infarction by rapid dry-strip creatine kinase MB, myoglobin, and troponin T // Am. Heart J. - 1998. - Vol. 135. -
P. 677-683.
189.Gerhardt W. et al. An improved rapid troponin T test with a decreased detection limit a multicentre study of the analytical and clinical performance in suspected myocardial damage // Scand. J. Clin. Lab Invest. - 1997. - Vol. 57. - P. 549-557.
190.Antman E.M. et al. Time to positivity of a rapid bedside assay for cardiac-specific troponin T predicts prognosis in acute coronary syndromes: a Thrombolysis in Myocardial Infarction (TIMI) 11A substudy // J. Am. Coll. Cardiol. - 1998. - Vol. 31. - P. 326-330.
191.Muller-Bardorff M. et al. Quantitative bedside assay for cardiac troponin T: a complementary method to centralized laboratory testing // Clin. Chem. - 1999. - Vol. 45. - P. 1002-1008.
192.Sabatine M.S. et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide // Circulation. - 2002. - Vol. 105. - P. 1760-1763.
193.Morrow D.A., de Lemos J.A. Benchmarks for the assessment of novel cardiovascular biomarkers // Circulation. - 2007. - Vol. 115. - P. 949-952.
194.Weber M., Hamm C. Novel biomarkers-the long march from bench to bedside // Eur. Heart J. - 2008. - Vol. 29. - P. 1079-81.
195.Dirksen M.S. et al. Cardiac multidetector-row computed tomography in patients with unstable angina // Am. J. Cardiol. - 2005. - Vol. 95. -
P. 457-461.
196.Cheitlin M.D. et al. ACC/AHA/ASE 2003. guideline update for the clinical application of echocardiography: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the
1997. Guidelines for the Clinical Application of Echocardiography) // Circulation. - 2003. - Vol. 108. - P. 1146-1162.
197.Kwong R.Y. et al. Incidence and prognostic implication of unrecognized myocardial scar characterized by cardiac magnetic resonance in diabetic patients without clinical evidence of myocardial infarction // Circulation. - 2008. - Vol. 118. - P. 1011-1020.
198.Fox K.A. et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE) // BMJ. - 2006. - Vol. 333. - P. 1091.
199.Granger C.B. et al. Predictors of hospital mortality in the global registry of acute coronary events // Arch. Intern. Med. - 2003. - Vol. 163. - P. 2345-2353.
200.de Araujo Goncalves P. et al. TIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS // Eur. Heart J. - 2005. - Vol. 26. - P. 865-872.
201.Antman E.M. et al. The TIMI risk score for unstable angina/non-ST elevation MI. A method for prognostication and therapeutic decision making // JAMA. - 2000. - Vol. 284. - P. 835-842.
202.Morrow D.A. et al. TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of infarcting myocardium early II trial substudy // Circulation. - 2000. - Vol. 102. - P. 2031-2037.
203.Morrow D.A. et al. Application of the TIMI risk score for ST-elevation MI in the National Registry of Myocardial Infarction 3 // JAMA. - 2001. - Vol. 286. - P. 1356-1359.
204.Singh M. et al. Scores for post-myocardial infarction risk stratification in the community // Circulation. - 2002. - Vol. 106. - P. 2309-2314.
205.Lee K.L. et al. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021. patients. GUSTO-I Investigators // Circulation. - 1995. -
Vol. 91. - P. 1659-1668.
206.Hochman J.S. et al. Cardiogenic shock complicating acute myocardial infarction-etiologies, management and outcome: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK? // J. Am. Coll. Cardiol. -
2000. - Vol. 36. (3. Suppl. A). - P. 1063-1070.
207.Lindholm M.G. et al. Cardiogenic shock complicating acute myocardial infarction. - prognostic impact of early and late shock development // Eur. Heart J. - 2003. - Vol. 24. - P. 258-265.
208.Schuchert A. et al. Prehospital testing for troponin T in patients with suspected acute myocardial infarction // Am. Heart J. - 1999. - Vol. 138. (1. Pt 1). - P. 45-48.
209.Richards A.M. et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction // Circulation. -
1998. - Vol. 97. - P. 1921-1929.
210.Schroder R. et al. Extent of early ST segment elevation resolution: a simple but strong predictor of outcome in patients with acute myocardial infarction // J. Am. Coll. Cardiol. - 1994. - Vol. 24. - P. 384-391.
211.de Lemos J.A. et al. Abciximab improves both epicardial flow and myocardial reperfusion in STelevation myocardial infarction. Observations from the TIMI 14. trial // Circulation. - 2000. - Vol. 101. - P. 239-243.
212.Smeeth L. et al. Risk of myocardial infarction and stroke after acute infection or vaccination // N. Engl. J. Med. - 2004. - Vol. 351. - P. 2611-2618.
213.Fedullo PF, Tapson VF. Clinical practice. The evaluation of suspected pulmonary embolism // N. Engl. J. Med. - 2003. - Vol. 349. - P. 1247-1256.
214.James P. et al. Relation between troponin T concentration and mortality in patients presenting with an acute // Stroke: observational study // BMJ. - 2000. - Vol. 320. - P. 1502-1504.
215.DePace N.L. et al. Intravenous nitroglycerin for rest angina. Potential pathophysiologic mechanisms of action // Arch. Intern. Med. - 1982. - Vol. 142. - P. 1806-1809.
216.Roubin G.S. et al. Intravenous nitroglycerine in refractory unstable angina pectoris // Aust. N. Z. J. Med. - 1982. - Vol. 12. - P. 598-602.
217.Curfman G.D. et al. Intravenous nitroglycerin in the treatment of spontaneous angina pectoris: a prospective, randomized trial // Circulation. - 1983. - Vol. 67. - P. 276-282.
218.Dellborg M., Gustafsson G., Swedberg K. Buccal versus intravenous nitroglycerin in unstable angina pectoris // Eur. J. Clin. Pharmacol. -
1991. - Vol. 41. - P. 5-9.
219.Theroux P. et al. A randomized study comparing propranolol and diltiazem in the treatment of unstable angina // J. Am. Coll. Cardiol. -
1985. - Vol. 5. - P. 717-722.
220.Lubsen J., Tijssen J.G. Efficacy of nifedipine and metoprolol in the early treatment of unstable angina in the coronary care unit: findings from the Holland Interuniversity Nifedipine/metoprolol Trial (HINT) // Am. J. Cardiol. - 1987. - Vol. 60. - P. 18A-25A.
221.Yusuf S., Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease. II. Unstable angina, heart failure, primary prevention with aspirin, and risk factor modification // JAMA. -
1988. - Vol. 260. - P. 2259-2263.
222.Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trial. The MIAMI Trial Research Group // Eur. Heart J. - 1985. - Vol. 6. - P. 199-226.
223.Kaplan K. et al. Intravenous nitroglycerin for the treatment of angina at rest unresponsive to standard nitrate therapy // Am. J. Cardiol. - 1983. - Vol. 51. - P. 694-698.
224.Parodi O. et al. Comparison of verapamil and propranolol therapy for angina pectoris at rest: a randomized, multiple-crossover, controlled trial in the coronary care unit // Am. J. Cardiol. - 1986. - Vol. 57. - P. 899-906.
225.Smith N.L. et al. Health outcomes associated with beta-blocker and diltiazem treatment of unstable angina // J. Am. Coll. Cardiol. - 1998. - Vol. 32. - P. 1305-1311.
226.Gibson R.S. et al. Prognostic significance and beneficial effect of diltiazem on the incidence of early recurrent ischemia after non-Q-wave myocardial infarction: results from the Multicenter Diltiazem Reinfarction Study // Am. J. Cardiol. - 1987. - Vol. 60. - P. 203-209.
227.Held P.H., Yusuf S., Furberg C.D. Calcium channel blockers in acute myocardial infarction and unstable angina: an overview // BMJ. - 1989. - Vol. 299. - P. 1187-1192.
228.Psaty B.M. et al. The risk of myocardial infarction associated with antihypertensive drug therapies // JAMA. - 1995. - Vol. 274. - P. 620-625.
229.Yusuf S., Held P., Furberg C. Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies // Am. J. Cardiol. - 1991. - Vol. 67. - P. 1295-1297.
230.Boden W.E. et al. Diltiazem in acute myocardial infarction treated with thrombolytic agents: a randomised placebo-controlled trial. Incomplete Infarction Trial of European Research Collaborators Evaluating Prognosis post-Thrombolysis (INTERCEPT) // Lancet. -
2000. - Vol. 355. - P. 1751-1756.
231.Borer J.S. Therapeutic effects of I(f) blockade: evidence and perspective // Pharmacol. Res. - 2006. - Vol. 53. - P. 440-445.
232.Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial // Lancet. - 2002. - Vol. 359. - P. 1269-1275.
233.Morrow D.A. et al. Effect of enoxaparin versus unfractionated heparin in diabetic patients with STelevation myocardial infarction in the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25. (ExTRACT-TIMI 25) trial // Am.
Heart J. - 2007. - Vol. 154. - P. 1078-841:084. e1.
234.McClellan K.J., Plosker G.L. Trimetazidine. A review of its use in stable angina pectoris and other coronary conditions // Drugs. - 1999. - Vol. 58. - P. 143-157.
235.Chaitman B.R. Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions // Circulation. - 2006. - Vol. 113. - P. 2462-2472.
236.Harrington R.A. et al. Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy // Chest. - 2004. - Vol. 126. (3. Suppl.). - P. 513S-548S.
237.Hirsh J. et al. Parenteral anticoagulants: american College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) // Chest. - 2008. - Vol. 133. (6. Suppl.). - P. 141S-159S.
238.Bassand J.P. et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes // Eur. Heart J. - 2007. - Vol. 28. - P. 1598-660.
239.Eikelboom J.W. et al. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis // Lancet. - 2000. - Vol. 355. - P. 1936-42.
240.Petersen J.L. et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview // JAMA. - 2004. - Vol. 292. - P. 89-96.
241.Yusuf S. et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes // N. Engl. J. Med. - 2006. - Vol. 354. - P. 1464-1476.
242.Hurlen M. et al. Warfarin: aspirin, or both after myocardial infarction // N. Engl. J. Med. - 2002. - Vol. 347. - P. 969-974.
243.Nguyen M.C. et al. Combining warfarin and antiplatelet therapy after coronary stenting in the Global Registry of Acute Coronary Events: is it safe and effective to use just one antiplatelet agent? // Eur. Heart J. - 2007. - Vol. 28. - P. 1717-1722.
244.Silber S. et al. [Percutaneous coronary interventions. Guidelines of the European Society of Cardiology-ESC.]. Kardiol Pol. - 2005. - Vol. 63. - P. 265-320. - discussion 321-323.
245.Stone GW, et al. Bivalirudin for patients with acute coronary syndromes // N. Engl. J. Med. - 2006. - Vol. 355. - P. 2203-2216.
246.Ferguson J.J. et al. Enoxaparin vs. unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial // JAMA. - 2004. - Vol. 292. - P. 45-54.
247.Montalescot G. et al. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention // N. Engl. J. Med. - 2006. - Vol. 355. - P. 1006-1017.
248.Theroux P. et al. Aspirin: heparin, or both to treat acute unstable angina // N. Engl. J. Med. - 1988. - Vol. 319. - P. 1105-11.
249.Theroux P. et al. Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina // Circulation. - 1993. -
Vol. 88. (5. Pt 1). - P. 2045-2048.
250.Cairns J.A. et al. One year mortality outcomes of all coronary and intensive care unit patients with acute myocardial infarction, unstable angina or other chest pain in Hamilton, Ontario, a city of 375,000. people // Can. J. Cardiol. - 1989. - Vol. 5. - P. 239-246.
251.Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients // BMJ. - 2002. - Vol. 324. - P. 71-86.
252.Yusuf S. et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation // N. Engl. J. Med. - 2001. - Vol. 345. - P. 494-502.
253.Gollapudi R.R. et al. Aspirin sensitivity: implications for patients with coronary artery disease // JAMA. - 2004. - Vol. 292. - P. 3017-3023.
254.Ramanuja S., Breall J.A., Kalaria V.G. Approach to “aspirin allergy” in cardiovascular patients // Circulation. - 2004. - Vol. 110: e1-4.
255.Eikelboom J.W. et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events // Circulation. - 2002. -
Vol. 105. - P. 1650-165.
256.Balsano F. et al. Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. The Studio della Ticlopidina nell’Angina Instabile Group // Circulation. - 1990. - Vol. 82. - P. 17-26.
257.Budaj A. et al. Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups // Circulation. - 2002. - Vol. 106. - P. 1622-1626.
258.Wiviott S.D. et al. Prasugrel compared with high loadingand maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44. trial // Circulation. - 2007. - Vol. 116. - P. 2923-2932.
259.Fox K.A. et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial // Circulation. - 2004. - Vol. 110. - P. 12021208.
260.Chan A.W. et al. Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET) // J. Am. Coll. Cardiol. -
2003. - Vol. 42. - P. 1188-1195.
261.Steinhubl S.R. et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention a randomized controlled trial // JAMA. - 2002. - Vol. 288. - P. 2411-2420.
262.Szuk T. et al. Effect of timing of clopidogrel administration on 30-day clinical outcomes. - P. 300-mg loading dose immediately after coronary stenting versus pretreatment 6. to 24. hours before stenting in a large unselected patient cohort // Am. Heart J. - 2007. - Vol. 153. -
P. 289-295.
263.Kandzari D.E. et al. Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization // J. Am. Coll. Cardiol. - 2004. - Vol. 44. - P. 2133-2136.
264.Montalescot G. et al. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial // J. Am. Coll. Cardiol. - 2006. - Vol. 48. -
P. 931-938.
265.Patti G. et al. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-
2. (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study // Circulation. - 2005. - Vol. 111. - P. 2099-2106.
266.von Beckerath N. et al. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen. Choose Between 3. High Oral Doses for Immediate Clopidogrel Effect) Trial // Circulation. - 2005. - Vol. 112. - P. 2946-2950.
267.Nguyen T.A., Diodati J.G., Pharand C. Resistance to clopidogrel: a review of the evidence // J. Am. Coll. Cardiol. - 2005. - Vol. 45. - P. 1157-1164.
268.Geisler T. et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation // Eur. Heart J. - 2006. - Vol. 27. - P. 2420-2425.
269.Gurbel PA. et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity // Circulation. - 2003. - Vol. 107. - P. 2908-2913.
270.Matetzky S. et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction // Circulation. - 2004. - Vol. 109. - P. 3171-3175.
271.Saw J. et al. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial // Circulation. - 2003. - Vol. 108. - P. 921-924.
272.Lim M.J. et al. Impact of combined pharmacologic treatment with clopidogrel and a statin on outcomes of patients with non-ST-segment elevation acute coronary syndromes perspectives from a large multinational registry // Eur. Heart J. - 2005. - Vol. 26. - P. 1063-1069.
273.Collet J.P. et al. Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes // Circulation. - 2004. -
Vol. 110. - P. 2361-2367.
274.Boersma E. et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a metaanalysis of all major randomised clinical trials // Lancet. - 2002. - Vol. 359. - P. 189-198.
275.Roffi M. et al. Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. Gradient of benefit related to the revascularization strategy // Eur. Heart J. - 2002. - Vol. 23. - P. 1441-1448.
276.Boersma E. et al. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention // Circulation. - 1999. - Vol. 100. - P. 2045-2048.
277.Kong D.F. et al. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease // Circulation. - 1998. - Vol. 98. - P. 2829-2835.
278.Roffi M. et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST- segment-elevation acute coronary syndromes // Circulation. - 2001. - Vol. 104. - P. 2767-2771.
279.Simoons M.L. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial // Lancet. - 2001. - Vol. 357. - P. 1915-1924.
280.A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators // N. Engl. J. Med. - 1998. - Vol. 338. - P. 1498-1505.
281.Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q- wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators // N. Engl. J. Med. - 1998. - Vol. 338. - P. 1488-1497.
282.Heeschen C. et al. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM Study Investigators. Platelet Receptor Inhibition in Ischemic Syndrome Management // Lancet. - 1999. -
Vol. 354. - P. 1757-1762.
283.Kong D.F. et al. Meta-analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions // Am. J. Cardiol. - 2003. - Vol. 92. - P. 651-655.
284.Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators // N. Engl. J. Med. - 1997. - Vol. 336. - P. 1689-1696.
285.Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade // Lancet. - 1998. - Vol. 352. - P. 87-92.
286.Lincoff A.M. et al. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3. Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators.Evaluation of 7E3. in Preventing Ischemic Complications // J. Am. Coll. Cardiol. - 1997. - Vol. 30. - P. 149-156.
287.Anderson K.M. et al. Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention // J. Am. Coll. Cardiol. - 2001. - Vol. 37. - P. 2059-2065.
288.Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study // Lancet. - 1997. - Vol. 349. - P. 1429-1435.
289.Hamm C.W. et al. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3. Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators // N. Engl. J. Med. - 1999. - Vol. 340. - P. 1623-1629.
290.Kastrati A. et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2. randomized trial // JAMA. - 2006. -
Vol. 295. - P. 1531-1538.
291.Moliterno D.J. et al. Outcomes at 6. months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascula-
risation with stent placement: the TARGET follow-up study // Lancet. - 2002. - Vol. 360. - P. 355-360.
292.Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention. IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary ThrombosisII // Lancet. - 1997. - Vol. 349. - P. 1422-1428.
293.Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial // Lancet. - 2000. - Vol. 356. - P. 2037-2044.
294.Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis // Circulation. - 1997. - Vol. 96. - P. 1445-1453.
295.Valgimigli M. et al. The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE Trial // J. Am. Coll. Cardiol. - 2004. - Vol. 44. - P. 14-19.
296.Giugliano R.P. et al. The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome-study design and rationale // Am. Heart J. - 2005. - Vol. 149. - P. 994-1002.
297.Stone G.W. et al. Routine upstream initiation vs. deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial // JAMA. - 2007. - Vol. 297. - P. 591-602.
298.Li Y.F., Spencer F.A., Becker R.C. Comparative efficacy of fibrinogen and platelet supplementation on the in vitro reversibility of competitive glycoprotein IIb/IIIa receptor-directed platelet inhibition // Am. Heart J. - 2002. - Vol. 143. - P. 725-732.
299.Cohen M. et al. Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. The Antithrombotic Combination Using Tirofiban and Enoxaparin // Am. Heart J. - 2002. - Vol. 144. - P. 470-477.
300.Ferguson J.J. et al. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-
3. (NICE-3) study // Am. Heart J. - 2003. - Vol. 146. - P. 628-634.
301.de Lemos J.A. et al. Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy: results from the A phase of the A-to-Z trial // Eur. Heart J. - 2004. - Vol. 25. - P. 1688-1694.
302.Alexander K.P. et al. Acute coronary care in the elderly, part II. ST-segment-elevation myocardial infarction: a scientific statement for healthcare professionals from the American Heart Association Council
on Clinical // Cardiology: in collaboration with the Society of Geriatric Cardiology // Circulation. - 2007. - Vol. 115. - P. 2570-2589.
303.Alexander K.P. et al. Acute coronary care in the elderly, part I. Non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical // Cardiology: in collaboration with the Society of Geriatric Cardiology // Circulation. - 2007. - Vol. 115. - P. 2549-2569.
304.O’Donoghue M. et al. Early invasive vs. conservative treatment strategies in women and men with unstable angina and non-ST-segment elevation myocardial infarction: a meta-analysis // JAMA. - 2008. -
Vol. 300. - P. 71-80.
305.Ryden L. et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) // Eur. Heart J. - 2007. - Vol. 28. - P. 88-136.
306.Stettler C. et al. Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis // BMJ. - 2008. - Vol. 337: a1331.
307.Go A.S. et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization // N. Engl. J. Med. - 2004. - Vol. 351. - P. 1296-1305.
308.Shlipak M.G. et al. Cardiovascular mortality risk in chronic kidney disease comparison of traditional and novel risk factors // JAMA. - 2005. - Vol. 293. - P. 1737-1745.
309.Hemmelgarn B.R. et al. Survival after coronary revascularization among patients with kidney disease // Circulation. - 2004. - Vol. 110. - P. 1890-1895.
310.Sabatine M.S. et al. Association of hemoglobin levels with clinical outcomes in acute coronary syndromes // Circulation. - 2005. - Vol. 111. - P. 2042-2049.
311.Nef H.M., Mollmann H., Elsasser A. Tako-tsubo cardiomyopathy (apical ballooning) // Heart. - 2007. - Vol. 93. - P. 1309-15.
312.Nef H.M. et al. Tako-Tsubo cardiomyopathy: intraindividual structural analysis in the acute phase and after functional recovery // Eur. Heart J. - 2007. - Vol. 28. - P. 2456-2464.
313.Moscucci M. et al. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE) // Eur. Heart J. - 2003. - Vol. 24. - P. 1815-1823.
314.Eikelboom J.W. et al. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes // Circulation. - 2006. - Vol. 114. - P. 774-782.
315.Rao S.V. et al. Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes // Eur. Heart J. - 2007. - Vol. 28. - P. 1193-1204.
316.Schroeder W.S., Gandhi P.J. Emergency management of hemorrhagic complications in the era of glycoprotein IIb/IIIa receptor antagonists, clopidogrel, low molecular weight heparin, and third-generation fibrinolytic agents // Curr. Cardiol. Rep. - 2003. - Vol. 5. - P. 310-317.
317.Rao S.V. et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes // JAMA. - 2004. -
Vol. 292. - P. 1555-1562.
318.Warkentin T.E. et al. Treatment and prevention of heparin-induced thrombocytopenia. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) // Chest. - 2008. -
Vol. 133. (6. Suppl.). - P. 340S-380S.
319.Srichai M.B. et al. Evaluating the benefits of glycoprotein IIb/IIIa inhibitors in heart failure at baseline in acute coronary syndromes // Am. Heart J. - 2004. - Vol. 147. - P. 84-90.
320.Yan A.T. et al. ST-segment depression in non-ST elevation acute coronary syndromes: quantitative analysis may not provide incremental prognostic value beyond comprehensive risk stratification // Am. Heart J. - 2006. - Vol. 152. - P. 270-276.
321.Bholasingh R. et al. Prognostic value of predischarge dobutamine stress echocardiography in chest pain patients with a negative cardiac troponin T // J. Am. Coll. Cardiol. - 2003. - Vol. 41. - P. 596-602.
322.Mehta S.R. et al. Routine vs. selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials // JAMA. - 2005. - Vol. 293. - P. 2908-2917.
323.Diderholm E. et al. The prognostic and therapeutic implications of increased troponin T levels and ST depression in unstable coronary artery disease: the FRISC II invasive troponin T electrocardiogram substudy // Am. Heart J. - 2002. - Vol. 143. - P. 760-767.
324.Invasive compared with non-invasive treatment in unstable coronary-artery disease. FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators // Lancet. - 1999. - Vol. 354. - P. 708-715.
325.McCullough P.A. et al. A prospective randomized trial of triage angiography in acute coronary syndromes ineligible for thrombolytic therapy. Results of the medicine versus angiography in thrombolytic exclusion (MATE) trial // J. Am. Coll. Cardiol. - 1998. - Vol. 32. - P. 596-605.
326.Hoenig M.R. et al. Early invasive versus conservative strategies for unstable angina & non-ST- elevation myocardial infarction in the stent era // Cochrane Database Syst. Rev. - 2006. - Vol. 3: CD004815.
327.Boersma E. et al. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461. patients. The PURSUIT Investigators // Circulation. - 2000. - Vol. 101. - P. 2557-2567.
328.Lagerqvist B. et al. A long-term perspective on the protective effects of an early invasive strategy in unstable coronary artery disease: two-year follow-up of the FRISC-II invasive study // J. Am. Coll. Cardiol.
-
2002. - Vol. 40. - P. 1902-1914.
329.Bavry A.A. et al. Benefit of early invasive therapy in acute coronary syndromes: a meta-analysis of contemporary randomized clinical trials // J. Am. Coll. Cardiol. - 2006. - Vol. 48. - P. 1319-1325.
330.Fox K.A. et al. 5-year outcome of an interventional strategy in non-ST-elevation acute coronary syndrome: the British Heart Foundation RITA 3. randomised trial // Lancet. - 2005. - Vol. 366. - P. 914920.
331.Boden W.E. et al. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. Veterans Affairs Non-Q- Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators // N. Engl. J. Med. - 1998. -
Vol. 338. - P. 1785-1792.
332.de Winter R.J. et al. Early invasive versus selectively invasive management for acute coronary syndromes // N. Engl. J. Med. - 2005. - Vol. 353. - P. 1095-1104.
333.Hirsch A. et al. Long-term outcome after an early invasive versus selective invasive treatment strategy in patients with non-ST-elevation acute coronary syndrome and elevated cardiac troponin T (the ICTUS trial): a follow-up study // Lancet. - 2007. - Vol. 369. - P. 827-835.
334.Cannon C.P. Revascularisation for everyone? // Eur. Heart J. - 2004. - Vol. 25. - P. 1471-1472.
335.Neumann F.J. et al. Evaluation of prolonged antithrombotic pretreatment (“cooling-off” strategy) before intervention in patients with unstable coronary syndromes: a randomized controlled trial // JAMA. -
2003. - Vol. 290. - P. 1593-1519.
336.Fox K.A. et al. Intervention in acute coronary syndromes: do patients undergo intervention on the basis of their risk characteristics? The Global Registry of Acute Coronary Events (GRACE) // Heart. - 2007. - Vol. 93. - P. 177-182.
337.Van de Werf F. et al. Access to catheterisation facilities in patients admitted with acute coronary syndrome: multinational registry study // BMJ. - 2005. - Vol. 330. - P. 441.
338.Lemos P.A. et al. Early outcome after sirolimus-eluting stent implantation in patients with acute coronary syndromes: insights from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry // J. Am. Coll. Cardiol. - 2003. - Vol. 41. - P. 2093-2099.
339.Mauri L. et al. Drug-eluting or bare-metal stents for acute myocardial infarction // N. Engl. J. Med. - 2008. - Vol. 359. - P. 1330-1342.
340.Eisenstein E.L. et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation // JAMA. - 2007. - Vol. 297. - P. 159-168.
341.McFadden E.P. et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy // Lancet. - 2004. - Vol. 364. - P. 1519-1521.
342.Fajadet J. et al. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial // Circulation. - 2006. -
Vol. 114. - P. 798-806.
343.Bavry A.A. et al. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials // Am. J. Med. - 2006. - Vol. 119. -
P. 1056-1061.
344.Maisel W.H. Unanswered questions-drug-eluting stents and the risk of late thrombosis // N. Engl. J. Med. - 2007. - Vol. 356. - P. 981-984.
345.Pieper K.S. et al. Differential treatment benefit of platelet glycoprotein IIb/IIIa inhibition with percutaneous coronary intervention versus medical therapy for acute coronary syndromes: exploration of methods // Circulation. - 2004. - Vol. 109. - P. 641-646.
346.Claeys M.J. et al. Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on peri-procedural myonecrosis // Eur. Heart J. - 2005. - Vol. 26. - P. 567-575.
347.Mauri L., Rogers C., Baim D.S. Devices for distal protection during percutaneous coronary revascularization // Circulation. - 2006. - Vol. 113. - P. 2651-2656.
348.Chu M.W. et al. Does clopidogrel increase blood loss following coronary artery bypass surgery? // Ann. Thorac. Surg. - 2004. - Vol. 78. -
P. 1536-1541.
349.Al-Khatib S.M. et al. Sustained ventricular arrhythmias among patients with acute coronary syndromes with no ST-segment elevation: incidence, predictors, and outcomes // Circulation. - 2002. - Vol. 106. - P. 309-312.
350.Solodky A. et al. The outcome of coronary artery bypass grafting surgery among patients hospitalized with acute coronary syndrome: the Euro Heart Survey of acute coronary syndrome experience // Cardiology. - 2005. - Vol. 103. - P. 44-47.
351.Mercado N. et al. One-year outcomes of coronary artery bypass graft surgery versus percutaneous coronary intervention with multiple stenting for multisystem disease: a meta-analysis of individual patient data from randomized clinical trials // J. Thorac. Cardiovasc. Surg. - 2005. - Vol. 130. - P. 512-519.
352.De Backer G. et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice // Eur. Heart J. - 2003. - Vol. 24. - P. 1601-1610.
353.Fox K. et al. Guidelines on the management of stable angina pectoris: executive summary. The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology // Eur. Heart J. - 2006. - Vol. 27. - P. 1341-1381.
354.Rahimi K. et al. Incidence, time course, and predictors of early malignant ventricular arrhythmias after non-ST-segment elevation myocardial infarction in patients with early invasive treatment // Eur. Heart J. - 2006. - Vol. 27. - P. 1706-1711.
355.Avezum A. et al. Impact of age on management and outcome of acute coronary syndrome: observations from the Global Registry of Acute Coronary Events (GRACE) // Am. Heart J. - 2005. - Vol. 149. - P. 67-73.
356.Abbate A. et al. Survival and cardiac remodeling benefits in patients undergoing late percutaneous coronary intervention of the infarct-related artery: evidence from a meta-analysis of randomized controlled trials // J. Am. Coll. Cardiol. - 2008. - Vol. 51. - P. 956-964.
357.Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000. patients.
Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group // Lancet. - 1994. - Vol. 343. - P. 311-322.
358.Di Mario C. et al. Immediate angioplasty versus standard therapy with rescue angioplasty after thrombolysis in the Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction (CARESS-in-AMI): an open, prospective, randomised, multicentre trial // Lancet. -
2008. - Vol. 371. - P. 559-568.
359.Fernandez-Aviles F. et al. Primary angioplasty vs. early routine post-fibrinolysis angioplasty for acute myocardial infarction with ST-segment elevation: the GRACIA-2. non-inferiority, randomized, controlled trial // Eur. Heart J. - 2007. - Vol. 28. - P. 949-960.
360.An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators // N. Engl. J. Med. - 1993. - Vol. 329. - P. 673-682.
361.A comparison of reteplase with alteplase for acute myocardial infarction. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators // N. Engl. J. Med. - 1997. - Vol. 337. - P. 1118-1123.
362.Van De Werf F. et al. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2. double-blind randomised trial // Lancet. - 1999. - Vol. 354. - P. 716722.
363.Barbash G.I. et al. Treatment of reinfarction after thrombolytic therapy for acute myocardial infarction: an analysis of outcome and treatment choices in the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (GUSTO I) and assessment of the safety of a new thrombolytic (ASSENT 2) studies // Circulation. - 2001. - Vol. 103. - P. 954-960.
364.Gershlick A.H. et al. Rescue angioplasty after failed thrombolytic therapy for acute myocardial infarction // N. Engl. J. Med. - 2005. -
Vol. 353. - P. 2758-2768.
365.Morrison L.J. et al. Mortality and prehospital thrombolysis for acute myocardial infarction. A metaanalysis // JAMA. - 2000. - Vol. 283. -
P. 2686-2692.
366.Boersma E. et al. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour // Lancet. - 1996. - Vol. 348. - P. 771-775.
367.Steg P.G. et al. Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial // Circulation. - 2003. - Vol. 108. - P. 28512856.
368.Gore J.M. et al. Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial. Global Use of Strategies to Open Occluded Coronary Arteries // Circulation. - 1995. - Vol. 92. - P. 28112818.
369.Berkowitz S.D. et al. Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. The Global Utilization of Streptokinase and Tissue Plasminogen activator for Occluded coronary arteries (GUSTO) I Investigators // Circulation. - 1997. - Vol. 95. - P. 2508-2516.
370.Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with STsegment elevation acute myocardial infarction (ASSENT-4. PCI): randomised trial // Lancet. - 2006. -
Vol. 367. - P. 569-578.
371.Le May M.R. et al. Combined angioplasty and pharmacological intervention versus thrombolysis alone in acute myocardial infarction (CAPITAL AMI study) // J. Am. Coll. Cardiol. - 2005. - Vol. 46. -
P. 417-424.
372.Sabatine M.S. et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation // N. Engl. J. Med. - 2005. - Vol. 352. - P. 1179-1189.
373.Chen Z.M. et al. Addition of clopidogrel to aspirin in 45,852. patients with acute myocardial infarction: randomised placebo-controlled trial // Lancet. - 2005. - Vol. 366. - P. 1607-1621.
374.de Bono DP, et al. Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial // Br. Heart J. - 1992. - Vol. 67. - P. 122-128.
375.The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. The GUSTO Angiographic Investigators // N. Engl. J. Med. - 1993. - Vol. 329. - P. 1615-1622.
376.Thompson P.L. et al. A randomized comparison of intravenous heparin with oral aspirin and dipyridamole 24. hours after recombinant tissue-type plasminogen activator for acute myocardial infarction. National Heart Foundation of Australia Coronary Thrombolysis Group // Circulation. - 1991. - Vol. 83. - P. 1534-1542.